The Obesity Drug Market: Novo's Bumpy Road Ahead The recent decline in Novo shares has sent shockwaves through the pharmaceutical industry, underscoring the challenges faced by the Danish company.
As CEO Mike Doustdar outlined the company's new growth strategy at its Capital Markets Day in London, investors were left underwhelmed.
Semaglutide, the active ingredient in weight loss and diabetes medicines Wegovy and Ozempic, is set to lose patent protection starting in 2032.